Retatrutide GuideLY3437943 Triple Agonist — Complete Research Reference by QSC Peptides

The pivotal retatrutide Phase 2 study — Jastreboff AM et al., New England Journal of Medicine, 2023 — enrolled 338 adults with obesity (BMI ≥ 30) in a 48-week double-blind, randomized, placebo-controlled trial of five LY3437943 (retatrutide) doses vs placebo.

Key findings from the 12mg dose arm (highest dose):

• ~24% average body weight reduction at 48 weeks — the highest ever reported in a Phase 2 obesity trial
• ~100% of participants achieved ≥5% weight loss
• ~83% achieved ≥15% weight loss at 12mg
• ~26% mean reduction in total body weight from baseline
• Weight loss was still accelerating at 48 weeks, suggesting Phase 3 outcomes may exceed Phase 2

The GCGR Mechanism — Why Retatrutide Leads

The GCGR (glucagon receptor) component is the key differentiator between Retatrutide and all prior GLP-1 class compounds. GCGR agonism contributes:

• Brown adipose thermogenesis: GCGR → Gs → cAMP → PKA → UCP1 upregulation in brown adipose tissue, increasing mitochondrial proton uncoupling and basal metabolic rate
• Hepatic fatty acid β-oxidation: GCGR in hepatocytes drives peroxisomal and mitochondrial fatty acid oxidation, rapidly depleting hepatic triglyceride stores — making Retatrutide the leading compound for NAFLD/NASH research
• Ketogenesis: GCGR drives hepatic ketone body production (β-hydroxybutyrate, acetoacetate), providing a GCGR-specific metabolic signature detectable in research
• Lipolysis: GCGR on adipocytes activates HSL for direct triglyceride hydrolysis, complementing GIPR-mediated lipolysis

QSC Peptides Retatrutide — Full Dose Range

QSC Peptides offers the most complete Retatrutide range available from any USA domestic supplier — enabling full dose-response research across the entire LY3437943 pharmacological landscape: 5mg, 10mg, 15mg, 20mg, 30mg, and 60mg per vial, in 10-vial and 20-vial kits.